The GPhC’s new standards for superintendent pharmacists: where does responsibility end?

Few pharmacists would disagree that superintendent pharmacists should be responsible for the systems they establish and oversee. The more difficult question is where responsibility for governance ends and responsibility for an individual practitioner’s actions begins.

That question lies at the heart of the General Pharmaceutical Council’s (GPhC) proposed standards for superintendent pharmacists. Developed alongside the wider pharmacy supervision reforms, the draft standards seek to clarify the superintendent pharmacist’s role, while placing greater emphasis on leadership, governance, and organisational culture.

As regulatory expectations continue to evolve, the distinction between a failure of governance and an individual’s misconduct may determine whether regulatory concerns arise at all.

The superintendent pharmacist’s role

The superintendent pharmacist occupies a unique statutory leadership position within a registered pharmacy business. Unlike the responsible pharmacist, whose duties relate to the safe and effective operation of an individual pharmacy at a particular time, the superintendent pharmacist provides strategic leadership and oversees the governance arrangements that support safe and effective pharmacy services across the organisation.

The recent supervision reforms attempt to preserve that distinction while enabling the professional regulator to define more fully the respective responsibilities of superintendent pharmacists and responsible pharmacists through professional standards and rules.

The GPhC’s draft standards identify five principal responsibilities for superintendent pharmacists:

• providing strategic and professional leadership;
• developing a workforce with the necessary skills, knowledge, and experience;
• delegating responsibly and maintaining clear lines of responsibility;
• establishing and strengthening governance arrangements; and
• ensuring that the pharmacy environment supports safe and effective care.

Taken together, the standards reinforce that the superintendent pharmacist’s role is not to supervise every professional decision personally, but to establish, maintain, and continually improve systems to ensure they are capable of delivering safe and effective pharmacy services.

Governance under the spotlight

The proposed standards reflect a broader trend across healthcare regulation. Increasingly, regulators seek to understand not only what happened when something goes wrong, but why it happened. Investigations routinely examine whether appropriate governance arrangements existed, foreseeable risks were identified, concerns were escalated appropriately, and lessons were learned.

This is not unique to pharmacy. The General Medical Council’s Good Medical Practice and the Nursing and Midwifery Council’s Code both require professionals in leadership roles to promote safe organisational cultures, respond appropriately to risks, and support effective governance.

Many would share the view that superintendent pharmacists should answer for inadequate governance, ineffective risk management, poor delegation, or failures to address known concerns under their watch. The more difficult cases arise where appropriate governance systems exist but an individual nevertheless apparently departs from them – for example, by deliberately falsifying records despite robust audit arrangements or repeatedly disregarding established procedures despite appropriate training and supervision.

In those circumstances, important regulatory questions may arise such as whether the superintendent pharmacist discharged their own professional responsibilities for leadership and oversight. Could the superintendent pharmacist reasonably have prevented what occurred through the exercise of appropriate leadership, governance, and process?

The existence of an adverse incident does not, by itself, establish that a superintendent pharmacist has fallen below the required professional standard. Instead, the assessment is likely to focus on whether governance arrangements were appropriate, foreseeable risks were identified and managed, concerns were escalated and addressed, and delegated responsibilities were subject to effective oversight.

Ultimately, the issue is whether there is a demonstrable connection between the alleged shortcomings and the superintendent pharmacist’s own discharge of their professional responsibilities. Equally, any assessment must remain proportionate. The standards should support robust governance without creating unrealistic expectations that a superintendent pharmacist can personally prevent every instance of individual misconduct across a large or complex organisation.

What stakeholders are saying

The, now concluded, consultation forms part of the wider implementation of the pharmacy supervision reforms, including changes due to come into force on 10 December 2026 under the Human Medicines (Authorisation by Pharmacists and Supervision by Pharmacy Technicians) Order 2025. The GPhC is expected to publish its final standards before those reforms take effect.

The consultation responses reveal broad support for the direction of travel. The principal debate concerns where the boundaries should be drawn. Several organisations have emphasised that the final standards should continue to recognise the distinct statutory roles of superintendent pharmacists and responsible pharmacists. Others have highlighted the need for the standards to remain proportionate and workable, particularly for organisations operating multiple pharmacy premises.

These concerns reflect an important principle. The challenge for the final standards will be to reinforce organisational leadership without creating unrealistic expectations of personal oversight. The existence of an adverse event does not, in isolation, necessarily demonstrate deficient governance, just as robust governance cannot eliminate every instance of individual misconduct.

Demonstrating governance in practice

From a regulatory defence perspective, one of the most practical consequences of the proposed standards is likely to be an even greater emphasis on evidence. Regulators are more likely to attach particular importance to evidence which demonstrates that governance arrangements operated effectively in practice.

This distinction often proves critical. Policies, governance frameworks, and standard operating procedures are important, but they rarely tell the whole story. Regulatory investigations frequently turn on contemporaneous evidence showing what decisions were taken, what risks were recognised, how concerns were escalated, and what action followed.

For superintendent pharmacists, the practical implication is clear. It may no longer be enough simply to point to well-designed governance arrangements. Increasingly, there will be a need to demonstrate, rather than simply assert, that the superintendent pharmacist exercised reasonable leadership and professional judgement, implemented appropriate systems, and responded appropriately when risks became apparent.

Superintendent pharmacists should take this opportunity to review not only their governance arrangements, but also how those arrangements are documented and evidenced. Useful contemporaneous records may include governance committee minutes, audit findings, risk registers, records of significant governance decisions, workforce training records, documented delegation arrangements, and records showing how concerns were monitored, investigated, and resolved. If regulatory scrutiny arises, such records may provide compelling evidence that appropriate leadership and oversight were exercised.

Takeaways

• Fundamentally, the debate surrounding the proposed standards is not about whether superintendent pharmacists should be responsible for the systems they oversee; few would argue otherwise. The more difficult question is how that responsibility should be assessed when something goes wrong.
• A superintendent pharmacist cannot personally supervise every branch, oversee every professional interaction, or prevent every instance of individual misconduct. Their role is to provide effective leadership, establish robust governance, and ensure that systems are capable of supporting safe and effective pharmacy practice across the organisation.
• For many superintendent pharmacists, the greatest regulatory risk may lie not in the absence of appropriate governance, but in the inability to evidence it when questions are later asked. In that respect, the proposed standards reflect an increasingly familiar principle across healthcare regulation: those in senior leadership roles will increasingly be judged not only by the systems they establish, but by their ability to demonstrate that those systems were actively maintained, reviewed, and improved. The extent to which the new standards will strike the right balance and fulfil the intended objective remains to be seen.

If you are a healthcare professional facing regulatory scrutiny or require advice or representation in relation to any professional regulatory matter, please contact Tracy Sell-Peters and Natasha Ricioppo.